AstraZeneca withdraws COVID-19 vaccine amid legal challenges and commercial decisions
In a significant development, UK-based pharmaceutical giant AstraZeneca has announced the global withdrawal of its COVID-19 vaccine, known as Covishield in India and Vaxzevria in ... Read More
ANGLE plc signs deal with AstraZeneca to develop Parsortix-based AR detection assay for prostate cancer studies
In a deal valued at £550,000, ANGLE plc (AIM:AGL, OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions, has secured an ... Read More
Breaking: AstraZeneca confesses vaccine side effects! Covishield’s shocking health risks exposed!
In a dramatic turn of events, British pharmaceutical giant AstraZeneca has admitted that its COVID-19 vaccine, Covishield, can cause a rare and serious side effect ... Read More
AstraZeneca’s Truqap, Faslodex combo recommended for EU approval for breast cancer treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) for approval within ... Read More
ANGLE plc collaborates with AstraZeneca on cutting-edge cancer detection technology
ANGLE plc, a leading innovator in liquid biopsy and circulating tumour cell (CTC) solutions, has announced a significant supplier agreement with global biopharmaceutical leader AstraZeneca ... Read More
AstraZeneca posts strong Q1 2024 results with significant revenue and EPS growth
AstraZeneca PLC has reported a notable performance in the first quarter of 2024, with total revenue reaching $12,679 million, marking a 19% increase at constant ... Read More
Voydeya approved in EU for enhanced treatment of PNH with residual haemolytic anaemia
Voydeya (danicopan), a first-in-class oral Factor D inhibitor from Alexion, AstraZeneca Rare Disease, has received approval from the European Commission as an add-on treatment to ... Read More
AstraZeneca’s Imfinzi demonstrates significant survival benefits in Phase 3 ADRIATIC trial
In a significant advancement for cancer treatment, AstraZeneca's Imfinzi (durvalumab) has emerged as the first and only immunotherapy to show a survival benefit in a ... Read More
AstraZeneca to acquire Fusion Pharmaceuticals to boost cancer radioconjugate development
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a pioneer in the development of ... Read More
AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio
AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments for rare endocrine diseases, in a deal ... Read More